Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12607000513415
Ethics application status
Not yet submitted
Date submitted
4/10/2007
Date registered
9/10/2007
Date last updated
9/10/2007
Type of registration
Prospectively registered
Titles & IDs
Public title
A pilot study of subcutaneous flumazenil infusion in the management of benzodiazepine dependence
Query!
Scientific title
Subcutaneous flumazenil infusion in the management of benzodiazepine dependence
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
benzodiazepine dependence
2423
0
Query!
Condition category
Condition code
Mental Health
2528
2528
0
0
Query!
Addiction
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
continuous subcutaneous flumazenil infusion at rate of 4mg/24 hours for 4 days, followed by 24 hours observation after ceasing infusion
Query!
Intervention code [1]
2145
0
Treatment: Drugs
Query!
Comparator / control treatment
nil
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
3427
0
percentage of patients entering treatment who complete benzodiazepine withdrawal and cease using benzodiazepines
Query!
Assessment method [1]
3427
0
Query!
Timepoint [1]
3427
0
day 5 after commencing flumazenil infusion
Query!
Secondary outcome [1]
5691
0
quantitative severity of benzodiazepine withdrawal as measured by Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) withdrawal scale
Query!
Assessment method [1]
5691
0
Query!
Timepoint [1]
5691
0
daily for 5 days during treatment
Query!
Secondary outcome [2]
5692
0
percentage of patients entering treatment who develop local tissue reaction to infusion
Query!
Assessment method [2]
5692
0
Query!
Timepoint [2]
5692
0
daily for 5 days during treatment
Query!
Eligibility
Key inclusion criteria
benzodiazepine dependent (daily use of benzodiazepine > 3 months at diazepam equivalent of 10mg or greater, with withdrawal symptoms on attempted cessation); wishing to withdraw from, and cease using benzodiazepines; 18 years or older; not pregnant or breastfeeding
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
under 18 years; pregnant or breastfeeding; unable or unwilling to give informed consent; medical condition that precludes cessation of benzodiazepine medication
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
all eligible, benzodiazepine dependent patients admitted to a community residential detoxification centre who wish to withdraw from benzodiazepines will be offered entry into the trial
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
3/12/2007
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
2677
0
Hospital
Query!
Name [1]
2677
0
St Vincent's, Melbourne
Query!
Address [1]
2677
0
PO Box 2900 Fitzroy Victoria 3065
Query!
Country [1]
2677
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
St Vincent's, Melbourne
Query!
Address
PO Box 2900 Fitzroy Victoria 3065
Query!
Country
Australia
Query!
Secondary sponsor category [1]
2418
0
None
Query!
Name [1]
2418
0
Query!
Address [1]
2418
0
Query!
Country [1]
2418
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
4596
0
St Vincent's, Melbourne, Human Research Ethics Committee
Query!
Ethics committee address [1]
4596
0
PO Box 2900 Fitzroy Victoria 3065
Query!
Ethics committee country [1]
4596
0
Australia
Query!
Date submitted for ethics approval [1]
4596
0
08/10/2007
Query!
Approval date [1]
4596
0
Query!
Ethics approval number [1]
4596
0
Query!
Summary
Brief summary
Aim: This project will assess the safety, effectiveness and patient acceptability of administering the medication, flumazenil, to treat benzodiazepine dependence by means of subcutaneous (under the skin) infusion rather than by intravenous infusion. Background: Benzodiazepines are a group of sedative drugs which are commonly prescribed for anxiety and insomnia. Examples include “valium”, “serepax”, and “mogadon”. Dependence on this group of drugs can occur rapidly with regular use, and successful withdrawal and treatment is very difficult. Long-term dependence on benzodiazepines, either prescribed or obtained illicitly through diversion, is therefore recognized as a major public health issue. Current treatment for benzodiazepine dependence usually involves a slow reduction in the benzodiazepine dose over weeks, but is frequently unsuccessful because of the withdrawal symptoms of anxiety and agitation that occur, and so patients remain on benzodiazepines long-term. Flumazenil is a medication that has recently been successfully used to treat benzodiazepine dependence by giving it as an intravenous infusion over several days. Unfortunately, using this method of intravenous infusion is complex and resource intensive, and this limits the availability of this form of treatment for many patients. This project is a pilot study to determine whether giving flumazenil by the simpler subcutaneous route would be an effective alternative that could make treatment available to many more patients.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
28089
0
Query!
Address
28089
0
Query!
Country
28089
0
Query!
Phone
28089
0
Query!
Fax
28089
0
Query!
Email
28089
0
Query!
Contact person for public queries
Name
11246
0
Professor Jon Currie
Query!
Address
11246
0
PO Box 2900 Fitzroy Victoria 3065
Query!
Country
11246
0
Australia
Query!
Phone
11246
0
61 3 9288 3467
Query!
Fax
11246
0
61 3 9288 2642
Query!
Email
11246
0
[email protected]
Query!
Contact person for scientific queries
Name
2174
0
Professor Jon Currie
Query!
Address
2174
0
PO Box 2900 Fitzroy Victoria 3065
Query!
Country
2174
0
Australia
Query!
Phone
2174
0
61 3 9288 3467
Query!
Fax
2174
0
61 3 9288 2642
Query!
Email
2174
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF